Fairmount Funds Management LLC Viridian Therapeutics, Inc.\De Transaction History
Fairmount Funds Management LLC
- $326 Million
- Q2 2025
A detailed history of Fairmount Funds Management LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Fairmount Funds Management LLC holds 3,459,913 shares of VRDN stock, worth $62.2 Million. This represents 14.83% of its overall portfolio holdings.
Number of Shares
3,459,913
Previous 3,445,813
0.41%
Holding current value
$62.2 Million
Previous $46.4 Million
4.13%
% of portfolio
14.83%
Previous 15.82%
Shares
6 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
82.7MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$96.7 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$87.6 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$81 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$79.6 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $717M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...